Keystone Financial Group (Kentucky)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,976
Closed -$205K 465
2025
Q2
$205K Buy
+2,976
New +$202K 0.02% 395
2025
Q1
Sell
-2,451
Closed -$211K 405
2024
Q4
$211K Sell
2,451
-481
-16% -$52K 0.02% 359
2024
Q3
$349K Buy
2,932
+86
+3% +$11.5K 0.04% 255
2024
Q2
$406K Buy
2,846
+453
+19% +$60K 0.15% 100
2024
Q1
$307K Buy
+2,393
New +$285K 0.04% 254

Other funds holding NVO

Keystone Financial Group (Kentucky)'s NVO Position: Q3 2025 in Review

Keystone Financial Group (Kentucky) sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 2,976 shares — an estimated $205K sold.

Keystone Financial Group (Kentucky) first reported a position in NVO in Q1 2024 and held it in 5 quarters. The position peaked at $406K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Keystone Financial Group (Kentucky) reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Keystone Financial Group (Kentucky) sold 2,976 Novo Nordisk shares in Q3 2025, an estimated $205K.
  • Keystone Financial Group (Kentucky) first reported a position in Novo Nordisk in Q1 2024 and held it in 5 quarters.
  • Keystone Financial Group (Kentucky)'s Novo Nordisk position peaked at $406K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Keystone Financial Group (Kentucky)'s 13F filing for Q3 2025, filed 14 Nov 2025.